会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • METHOD FOR CHANGING THE REFRACTIVE POWER OF AN EYE
    • 改变眼睛屈光力的方法
    • WO9829069A2
    • 1998-07-09
    • PCT/US9723794
    • 1997-12-29
    • ALLERGAN INC
    • STERN MICHAEL EPOWER DAVID FCHEETHAM JANET K
    • A61F9/013A61K38/39A61B3/103A61B3/107A61K31/00A61K31/19A61K31/195A61K31/38A61K31/39A61K31/40A61K31/405A61K31/465A61K31/57A61K31/715
    • A61F9/013A61K38/39
    • A method provides for changing the refractive power of an eye, and includes the step of selecting a dioptic correction for an eye without compromise for regression of refractive power due to biological response to a change in corneal profile, changing the corneal profile of the eye in order to change the refractive power of the eye to the selected dioptic, (e.g. by laser of surgical procedures) and limiting regression in corneal profile due to the biological response at about to the selected diopter by applying to the corneal composition comprising an agent for controlling the biological response. The agent comprised in the composition may be a steroid, a non-steroidal anti-inflammatory agent or a basement membrane component. The change in the refractive power is intended to achieve emmetropia. The method of the present invention allows the correction of refractive/focusing disorders of the eye such as myopia, hyperopia, (a)stigmatism and so on.
    • 一种方法提供了改变眼睛屈光度的方法,并且包括以下步骤:选择用于眼睛的屈光矫正,而不会因角膜分布变化的生物反应而折射力的回归而折中,改变眼睛的角膜轮廓 (例如通过外科手术的激光)来改变眼睛的屈光度,并且通过将角膜组合物应用于包含用于控制的药剂的角膜组合物,由于通过选择的屈光度的生物反应而限制角膜分布的退化 生物反应。 包含在组合物中的药剂可以是类固醇,非甾体抗炎剂或基底膜组分。 屈光力的变化旨在实现正视。 本发明的方法允许校正眼睛的屈光/聚焦障碍,例如近视,远视,(a)斑驳等。
    • 7. 发明申请
    • USE OF PLATELET DERIVED GROWTH FACTOR IN OPHTHALMIC WOUND HEALING
    • 使用平板电脑衍生生长因子进行OPHTHALMIC WOUND HEALING
    • WO9316719A3
    • 1993-10-28
    • PCT/US9301731
    • 1993-02-24
    • ALLERGAN INC
    • STERN MICHAEL EWHEELER LARRY ANICOLSON MARGERY A
    • A61K38/22A61K38/00A61K38/18A61P27/02A61P43/00C07K14/49A61K37/02C07K13/00
    • C07K14/49A61K38/1858
    • A method of accelerating corneal wound healing and/or improving the quality of wound healing in a mammal comprises: (1) providing an ophthalmically compatible solution of platelet-derived growth factor; and (2) applying the solution to the cornea of a mammal at the time of or subsequent to occurrence of a corneal wound in a quantity sufficient to accelerate clinically detectable healing, the healing being accelerated through proliferation of epithelial cells and/or keratocytes of the cornea stimulated by application of the platelet-derived growth factor to the cornea. The method also improves the quality of wound healing. The platelet-derived growth factor can be selected from the group consisting of the AA isoform, the AB isoform, the BB isoform, and mixtures thereof. A preferable form of platelet-derived growth factor is a recombinantly-derived refolded B-chain homodimer of 119 amino acids, having the amino acid sequence of S-L-G-S-L-T-I-A-E-P-A-M-I-A-E-C-K-T-R-T-E-V-F-E-I-S-R-R-L-I-D-R-T-N-A-N-F-L-V-W-P-P-C-V-E-V-Q-R-C-S-G-C-C-N-N-R-N-V-Q-C-R-P-T-Q-V-Q-L-R-P-V-Q-V-R-K-I-E-I-V-R-K-K-P-I-F-K-K-A-T-V-T-L-E-D-H-L-A-C-K-C-E-T-V-A-A-A-R-P-V-T-R-S-P-G-G-S-Q-E-Q-R. The concentration of platelet-derived growth factor in the solution can be from about 10 νg/ml to about 1000 νg/ml, preferably from about 50 νg/ml to about 500 νg/ml, and most preferably about 100 νg/ml. The invention also comprises pharmaceutical compositions for application to the cornea of a mammal for accelerating corneal wound healing and/or improving the quality of wound healing and tablets for preparation of the pharmaceutical compositions.